Study of Arsenic Trioxide in Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the effect of an anticancer drug, Arsenic Trioxide, in
patients with small cell lung cancer who have failed at least one standard chemotherapy
regimen as well as patients who are unable to tolerate the standard treatment for their
cancer. The investigators seek to establish the safety of and efficacy of Arsenic Trioxide in
this patient group. The study will include up to 36 participants with small cell lung cancer.
The investigators want to find out what effects, good or bad, that the study drug has on your
cancer. This study will also look at specific biomarkers in your blood and in the tumor
tissue which may help the investigators to determine if the levels of these biomarkers are
related to tumor response to treatment.
Arsenic Trioxide, also known by the brand name, Trisenox, is a chemotherapy drug approved by
the Food and Drug Administration (FDA) for the treatment of a specific type of blood cancer
called Acute Promyelocytic Leukemia. It works in part by making cancer cells become more
mature thereby stopping them from growing in number and more likely to die off.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
Cephalon National Cancer Institute (NCI) Teva Pharmaceuticals USA